Valeant Pharmaceuticals International Inc. may face a significant challenge in getting a clear answer on whether its plaque psoriasis candidate Siliq (brodalumab) has an increased suicide risk – and efforts to reduce that risk may be part of the problem.
If the product is approved, Valeant is planning to assess Siliq’s potential risk of suicide ideation and behavior with a...





